A Sample-Size-Optimal Bayesian Procedure for Sequential Pharmaceutical Trials

DOI10.2307/2532784MaRDI QIDQ4842862zbMATH OpenOpenAlexWikidataFDO

Authors Noel Cressie, Jonathan Biele

Publication date 11 September 1995

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.2307/2532784

zbMATH Keywords

backward inductionclinical trialsgroup-sequential procedureoptimal stoppingpharmaceutical trialpredictive distributionsample- size ruleVPRT

Mathematics Subject Classification ID

Bayesian inference (62F15) Sequential statistical analysis (62L10) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
• A Bayesian decision approach for sample size determination in phase II trials
• Optimal sequentially planned decision procedures. With the assistance of Günter Duscha, Josef Lübbert and Thomas Meyerthole
• On Bayesian group sequential sampling procedures
• Approximately optimal designs for phase II clinical studies

Cited in

(6)

• Methodology and application of adaptive and sequential approaches in contemporary clinical trials
• Testing simultaneous hypotheses in pharmaceutical trials: a bayesian approach
• Approaches for Optimal Sequential Decision Analysis in Clinical Trials
• Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
• Bayesian randomized clinical trials: A decision-theoretic sequential design
• scientific article; zbMATH DE number 5243988 (Why is no real title available?)

This page was built for publication: A Sample-Size-Optimal Bayesian Procedure for Sequential Pharmaceutical Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4842862)